



Review

DOI: <http://dx.doi.org/10.14259/or.v1i1.81>

Targeting PI3K/AKT/mTOR Pathway and Mutant EGFR to Overcome Resistance to Tyrosine Kinase Inhibitors in Mutant EGFR-Mediated Lung Cancer

XIAOLING SONG*

¹Department of Pathology and Yale Cancer Center, Yale University School of Medicine, New Haven CT, USA 06510**Article Info:** Received: November 10th, 2013; Accepted: November 15th, 2013

ABSTRACT

Lung cancer is the leading cause of cancer-related deaths in the United States and worldwide. Targeted therapy of mutant Epidermal Growth Factor Receptor (EGFR)-mediated lung cancer with tyrosine kinase inhibitors (TKIs) has greatly improved clinical outcome. However, lung tumors inevitably develop resistance to TKI drugs within a year. Identified resistant mechanisms include: acquisition of a secondary mutation in EGFR (T790M) or mutations in PI3KCA, amplification of MET tyrosine kinase receptor, overexpression of MET ligand Hepatocyte Growth Factor (HGF), or transformation to small cell lung cancer. Many of these resistant mechanisms involve the reactivation of the phosphatidylinositol 3-kinase (PI3K) /AKT/ mammalian target of rapamycin (mTOR) pathway in tumor cells. Studies have shown that inhibition of the PI3K/AKT/mTOR pathway suppressed the growth of EGFR mutant TKI-resistant lung cancer cell lines; furthermore, a combination of PI3K/AKT/mTOR inhibitor and an EGFR TKI enhanced tumor regression in xenograft models. The data reviewed in this literature suggests that a combinatory therapy of PI3K/AKT/mTOR inhibitors with EGFR TKIs provides a promising way to overcome EGFR TKI resistance.

Keywords: EGFR mutant, Lung cancer, TKI resistance, PI3K/AKT/mTOR pathway, mTOR inhibitor, Tumor regression

Introduction

Treatment for lung cancer has been a big challenge in the United States, and the five-year survival rate of lung cancer is only about 17% [1]. Lung adenocarcinoma is the major histopathological subtype of lung cancer and is implicated in about 40% of lung cancer patients. Recent research advances in the identification of driver events, such as Epidermal Growth Factor Receptor (EGFR) mutations, in lung adenocarcinoma have greatly promoted precision medicine. EGFR activating mutations are found in 10-15% of lung adenocarcinomas [2-4]. These mutations lead to constitutive activation of the EGFR receptor [5,6] and are sufficient to induce lung tumors in mice [7,8]. Tumors bearing activating EGFR mutations are sensitive to treatment with reversible EGFR tyrosine kinase inhibitors (TKIs) with a response rate of about 70%, which is more

effective compared to a 40% response rate with chemotherapy [9,10]. However, patients who initially respond to TKI treatment inevitably develop resistance on average within about a year. Currently, the resistance to EGFR TKIs remains a major problem for lung cancer patients. Various strategies are in development to circumvent EGFR TKI-resistance including a combinatory treatment with PI3K/AKT/mTOR inhibitors and EGFR TKIs. This review will discuss the role of PI3K/AKT/mTOR pathway in EGFR TKI-resistant lung cancers, and focuses on the recent research advances made in combined blockade of the PI3K/AKT/mTOR pathway and mutant EGFR.

EGFR TKI Resistant Mechanisms Involve Reactivation of The PI3K/AKT/mTOR pathway

Activating mutations of EGFR, either deletions in exon 19 or a point mutation L858R in exon 21, constitutively activate EGFR downstream signaling including the mitogen-activated protein (MAP) kinase pathway and the PI3K/AKT/mTOR pathway (Fig. 1). Upon activation, receptor tyrosine kinases

*Corresponding Author

Xiaoling Song, PhD

Department of Pathology and Yale Cancer Center, Yale University School of Medicine, 25 York Street, New Haven, CT 06510 USA.

Phone: +1 (203) 737-6215

Email: xiaoling.song@yale.edu

(RTKs), including EGFR, activate PI3 kinase, which converts phosphatidylinositol-3,4-bisphosphate (PI(3,4)P₂) to phosphatidylinositol-3,4,5-triphosphate (PI(3,4,5)P₃). PIP₃ then recruits PDK-1 (phosphoinositide-dependent kinase 1) and AKT to cell membrane, and leads to activation of AKT by PI3K and PDK1. AKT then dissociates from plasma membrane, and activates a variety of downstream targets in the cytoplasm and nucleus to regulate cell growth, proliferation, and survival. One important AKT downstream mediator is mTOR, which phosphorylates eIF4E binding proteins (4E-BPs) and S6 kinases and regulates protein synthesis (Fig. 1).

Mounting evidence indicates that many TKI-resistant mechanisms in EGFR mutant lung cancer involve reactivation of the PI3K/AKT/mTOR pathway (Fig. 1). First, mutant EGFR

activates the PI3K/AKT/mTOR pathway by forming a homo-dimer or hetero-dimer with ERBB3. EGFR with acquired resistant mutation T790M, which is found in about 50% of resistance cases, causes sustained activation of ERBB3 and AKT in the presence of reversible EGFR tyrosine kinase inhibitors, gefitinib or erlotinib [11]. Second, the PI3K/AKT/mTOR pathway can be activated by receptor tyrosine kinases such as MET or Insulin-like growth factor 1 receptor (IGFIR). MET amplification has been reported in 5-22% of TKI-resistant tumors with EGFR mutation [12-14]. In a subset of EGFR TKI-resistant lung cancer with MET amplification, MET constitutively activates the PI3K/AKT/mTOR pathway in the presence of gefitinib by transactivating ERBB3 [15]. Third, amplification of MET ligand HGF also leads to sustained activation of AKT without involving EGFR or ERBB3 [16].




Figure 1: Different EGFR TKI-resistant mechanisms involve reactivation of the PI3K/AKT/mTOR pathway: EGFR TKI resistant mechanisms include: 1) acquisition of a second mutation T790M on mutant EGFR, 2) amplification of MET, 3) over-expression of HGF, 4) PI3KCA mutation, and 5) other RTK alterations (eg. IGFIR) lead to reactivation of the PI3K/Akt pathway in the presence of EGFR reversible tyrosine kinase inhibitors. Notably, mutant EGFR do not need the presence of EGF to be activated. Inhibition of mTORC1 by rapamycin and its analogs leads to feedback activation of AKT through mTORC2 and IRS1.

Fourth, PI3KCA mutation, p110αE545K, has been reported in about 5% of acquired resistance cases [12]. The oncogenic mutation of PI3KCA causes prolonged phosphorylation of AKT and reduced apoptosis of cancer cells in the presence of gefitinib [11]. Based on the observations that many TKI-resistant mechanisms relate to reactivation of the PI3K/AKT/mTOR pathway, it is likely that the combined treatment with PI3K/AKT/mTOR inhibitors and EGFR TKIs might overcome resistance in EGFR mutant TKI-resistant lung cancer.

Feedback Activation of AKT Limits Single Agent Use of mTOR Inhibitors

mTOR inhibitors rapamycin and its derivatives are the most extensively studied inhibitors of the PI3K/AKT/mTOR pathway. These inhibitors form a complex with FKBP12 to inhibit mTOR complex 1 (mTORC1) activity and cause G1 cell cycle arrest [17]. mTORC1 downstream targets p70 S6 kinase (S6K) was shown inhibited by rapamycin in several lung cancer cell lines [18]. However, S6K negatively regulates both Insulin Receptor Substrate 1 (IRS-1) and mTORC2 which both activate AKT, and rapamycin cannot block the activity of mTORC2; therefore, blockade of mTORC1 eventually activates AKT by feedback activation of IRS-1 and mTORC2 [18]. Feedback activation of AKT greatly attenuates the anti-proliferation effect of rapamycin in lung cancer cells [17] (Fig. 1).

Due to the feedback regulation of the PI3K/AKT/mTOR pathway by mTOR inhibitors, a combined treatment of an mTOR inhibitor with a PI3K or AKT inhibitor might be necessary to fully inhibit the PI3K pathway. Alternatively, inhibitors that target both mTORC1 and mTORC2 might overcome the feedback regulation of the PI3K/AKT/mTOR pathway and enhance drug efficacy. A variety of novel inhibitors against multiple mediators of the PI3K/AKT/mTOR pathway have been investigated, including pan-PI3K inhibitors [19] and dual PI3K/mTOR inhibitors [20] (Fig. 3). It has been shown that combined use of rapamycin with LY294002, an inhibitor of both mTOR kinase and phosphatidylinositol 3-kinase (PI3K), in lung cancer cells greatly enhanced the inhibition effect of rapamycin on growth and colony formation [18]. A different study showed that using rapamycin with a dual inhibitor of PI3K and mTOR (NVP-BE235) synergistically inhibited the growth of both EGFR mutant and EGFR wild type non-small cell lung cancer [21].

In TKI-resistant EGFR mutant lung cancer cells, both the PI3K/AKT/mTOR pathway and the MAPK pathway are highly activated, and mTOR can be activated by the MAPK pathway [22] (Fig. 1). Therefore, PI3K/AKT/mTOR pathway inhibitor alone is not enough to achieve maximum inhibition; hence, EGFR TKIs, which inhibit both the PI3K/AKT/mTOR pathway and the MAPK pathway, are essential to inhibit of lung cancer cell growth. A combination of PI3K/mTOR pathway inhibitors with EGFR TKIs is thus necessary to treat the TKI-resistant lung cancer.

Inhibitors of PI3K Signaling Pathway in Combination With EGFR TKI Reverse Lung Tumor Progression

Because the PI3K/AKT/mTOR pathway is highly activated in many EGFR mutant TKI-resistant lung cancer, strategies that inhibit the PI3K/AKT/mTOR pathway have been investigated in combination with EGFR TKIs. Some of these inhibitors have been shown to work cooperatively with EGFR TKIs to regress the growth of TKI-resistant lung cancer cells.

A. mTOR inhibitors: To monitor the erlotinib resistant mechanisms of mutant EGFR-mediated lung cancer, mouse models have been built to express mutant EGFR with both activating mutation L858R and the gatekeeper resistant mutation T790M [23]. In these TKI-resistant mouse models, an irreversible EGFR TKI (HKI-272) has been tested alone or in combination with mTOR inhibitor rapamycin [23,24]. HKI-272 inhibited the activity of both EGFR and ERBB2. ERBB2 is a member of the EGFR family and is frequently activated in mutant EGFR-mediated lung tumor. Although rapamycin alone did not result in tumor regression, and HKI-272 alone led to regression of peripheral murine lung tumors, a combination of HKI-272 and rapamycin led to extensive regression of both peripheral and bronchial tumors induced by resistant EGFR mutants. However, although erlotinib synergized with rapamycin in inhibiting the growth of some EGFR wild type lung cancer cell lines, there was no synergism observed in EGFR mutant TKI-resistant lung cancer cells [23, 25]. These studies suggest that combination of mTOR inhibitors with the second generation irreversible EGFR tyrosine kinase inhibitors provide a better way to treat EGFR mutant TKI-resistant lung cancer with T790M mutation.

B. AKT kinase-interacting protein 1 (AKI1) targeting: Adaptor scaffold protein AKI1 is another ideal target in blocking the PI3K/AKT pathway. In EGFR wild type cells, AKI1 recruits both PDK1 and AKT to phosphorylated EGFR, which in turn leads to activation of the AKT-mediated signaling [26] (Fig. 2). In EGFR mutant lung cancer cells, AKI1 is broadly expressed [26], and mutant EGFR is constitutive active [5,6]. Thus, AKI1 constitutively activates the AKT/mTOR pathway in these cancer cells even in the absence of EGFR ligands [26] (Fig. 2). Data showed that knockdown of AKI1 by siRNA decreased the phosphorylation level of AKT and S6, promoted cell apoptosis, and significantly inhibited the growth of TKI-resistant EGFR mutant lung cancer cells [26]. Concurrent treatment with AKI1 siRNA and EGFR irreversible TKIs, such as HKI-272, afatinib(BIBW2992) or WZ4002, potentiated the growth inhibition effect of those TKIs in lung cancer cells [26].

C. PI3K inhibitors: Increased level of HGF confers EGFR TKI resistance by activating downstream the MEK/ERK pathway and the PI3K/AKT pathway (Fig. 1). Although mTOR inhibitors reduced the cell viability of EGFR mutant lung cancer cells in the presence of HGF, and reduced the tumor

growth of HGF-mediated TKI-resistant xenograft; mTOR inhibition did not sensitizing EGFR mutant lung cancer cells to erlotinib in HGF-mediated resistance [27]. On the contrary, a short time exposure of class I PI3K inhibitor PI-103 with gefitinib treatment produced a prolonged inhibition of AKT phosphorylation, promoted cell apoptosis, and led to tumor regression in HGF-mediated TKI-resistant xenograft model [28].

D. Dual inhibitors of PI3K/mTOR: H1650 is a lung adenocarcinoma cell line expressing mutant EGFR (exon 19 deletion) with PTEN loss and EGFR TKI resistance [32]. Using a dual inhibitor of PI3K and mTOR (NVP-BEZ235) with erlotinib synergistically decreased cell viability of H1650 [21].

E. Inhibitors of other factors in the PI3K/AKT/mTOR pathway: Glycolysis inhibitor 2DG (2-deoxy-d-glucose) enhanced afatinib sensitivity in T790M-mediated TKI-resistant lung cancer cell lines by phosphorylating AMP-activated protein kinase (AMPK) and inhibiting mTOR [33]. In addition, MET inhibitor bufalin blocked the activation of the PI3K/AKT/mTOR pathway and sensitized HGF-mediated TKI-resistant cells to gefitinib by decreasing the protein levels of c-Met [29-31].

Clinical Trials Using PI3K/AKT/mTOR Pathway Inhibitors and EGFR TKIs For Treatment of EGFR Mutant Lung Cancer

Observations from *in vitro* and *in vivo* experiments that PI3K/AKT/mTOR inhibitors work cooperatively with EGFR TKIs to overcome resistance have led to several clinical trials [34, 35]. Most ongoing clinical trials use the combination of PI3K/AKT/mTOR inhibitors with the first generation reversible EGFR

inhibitor erlotinib or gefitinib. These combinatory inhibitors being tested include (Fig. 3): 1) *Pan-PI3K inhibitor*: XL147 with erlotinib (Phase I, Trial# NCT00692640); 2) *dual PI3K/mTORC1/2 inhibitor*: XL765 + erlotinib (phase I, NCT00777699); 3) *pan-AKT inhibitor*: MK-2206 + gefitinib (phase I, NCT01147211) or MK-2206 + erlotinib or AZD6244 (MEK inhibitor, phase II, trial # NCT01248247) and MK-2206 + erlotinib (phase II, trial # NCT01294306). Because the second-generation irreversible EGFR TKIs are more potent than the first generation reversible TKIs in inhibition of mutant EGFR activity, using irreversible EGFR inhibitors more likely achieves a better response in EGFR mutant TKI-resistant lung cancer than using the first generation of TKIs especially in those T790M-mediated resistance cases. Recently, a second-generation EGFR TKI afatinib (Boehringer Ingelheim Pharmaceuticals, Inc.) has been approved as a first line therapy for lung cancer patients with EGFR mutations [36]. An ongoing clinical trial (Phase Ib, NCT00993499) using afatinib plus mTOR inhibitor Sirolimus (Rapamune, Boehringer Ingelheim Pharmaceuticals) to treat patients with relapsed EGFR mutant lung adenocarcinoma shows more promise than erlotinib or gefitinib treatment.

Discussion and Conclusions

The PI3K/AKT/mTOR pathway is highly activated in resistance to chemotherapy and EGFR-targeted therapy of lung cancer. Although many antagonists of the PI3K/AKT/mTOR pathway have been developed, a combined treatment with multiple inhibitors or dual inhibitors is more efficient in inhibition of the PI3K/AKT/mTOR pathway due to feedback regulation. Advances have been made in both research and




Figure 2: AKI1 associates PDK1 and AKT with activated EGFR: A) In the absence of EGF, AKI1 does not bind AKT and EGFR. After addition of EGF, EGFR is activated and associated with AKT and PDK1 via AKI1. B) Mutant EGFR is highly active even in the absence of EGF. Mutant EGFR, both activating and resistant conferring, is constitutively associated with AKT and PDK1 via AKI1. C) AKI1 knockdown dissociates AKT and PDK1 from EGFR and leads to inhibition of AKT activity. This figure was adapted from Yamada [26].

There are also other rational combination drug therapies in development to overcome EGFR TKI resistance in EGFR-

mutant lung cancer. First example is combined therapy of EGFR tyrosine kinase inhibitor and MET kinase inhibitor. Treatment with the combination of MET inhibitors and EGFR TKIs may overcome the resistance mediated by MET amplification or overexpression of MET ligand HGF. A combined therapy of dual AXL/c-MET inhibitor (CEP40783) and erlotinib has significantly enhanced tumor regression in erlotinib-resistant Champions TumorGraft™ models [37]. Currently, the efficacy of combination therapy of using EGFR and MET inhibitor is being tested by phase I clinical trial (NCT01121575). Another example is blocking both ERBB3 and EGFR to overcome TKI resistance. ERBB3 has shown involved in MET-mediated TKI resistance. Co-administration of ERBB3 antibody MM121 with EGFR antibody cetuximab led to the regression of EGFR TKI resistant tumors expressing T790M in mouse models [38], which has spurred an ongoing




Figure 3: Inhibitors have been developed to target mutant EGFR and the PI3K/Akt/mTOR pathway in treatment of lung adenocarcinoma. Inhibitors of the PI3K/Akt/mTOR pathway that are undergoing investigation for treatment of lung adenocarcinoma are listed. Inhibitors of the PI3K/Akt/mTOR pathway or mutant EGFR that are used in current clinical trials to overcome EGFR TKI resistance are shown in blue.

phase I clinical trial of using MM-121 and cetuximab (NCT01451632) in advanced non-small cell lung cancers. Simultaneously, a phase I/2 clinical trial using MM-121 with erlotinib as a standard therapy is ongoing (NCT00994123). While using specific inhibitors/antibodies against MET or ERBB3 provides benefits to a subset of patients, targeting both the PI3K/AKT/mTOR pathway mediators and mutant EGFR is likely to be a promising therapeutic strategy for a broad range of lung cancer patients. Furthermore, due to the heterogeneity of lung cancer, more than one resistant mechanism may exist in the same patient; thus, targeting the common PI3K/AKT/mTOR pathway downstream from several resistant mechanisms likely provides a superior way to overcome EGFR TKI resistance.

Acknowledgements

XS received funding support from Yale Cancer Center and Uniting Against Lung Cancer. I thank Amlak Bantikassegan and Dr. Z. Shao for their critical reading and revising of the manuscript.

References

1. United States Department of Health and Human Services. National Institutes of Health. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2010. <http://seer.cancer.gov/statfacts/html/lungb.html> 2013.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, et al.: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *N Engl J Med* 2004, **350**:2129-2139.
3. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al.: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004, **304**:1497-1500.
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al.: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. *Proc Natl Acad Sci U S A* 2004, **101**:13306-13311.
5. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, et al.: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. *PLoS Med* 2005, **2**:e313.
6. Yun CH, Boggon TJ, Li Y, Woo MS, Greulich H, Meyerson M, Eck MJ: Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. *Cancer Cell* 2007, **11**:217-227.
7. Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R, et al.: The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. *Cancer Cell* 2006, **9**:485-495.
8. Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE: Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. *Genes Dev* 2006, **20**:1496-1510.
9. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al.: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. *N Engl J Med* 2010, **362**:2380-2388.
10. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. *N Engl J Med* 2009, **361**:947-957.
11. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borras AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, et al.: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. *J Clin Invest* 2006, **116**:2695-2706.
12. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger S, Cospers AK, et al.: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med* 2011, **3**:75ra26.
13. Turke AB, Zejnullahu K, Wu YL, Song Y, Dias-Santagata D, Lifshits E, Toschi L, Rogers A, Mok T, Sequist L, et al.: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. *Cancer Cell* 2010, **17**:77-88.
14. Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al.: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. *Proc Natl Acad Sci U S A* 2007, **104**:20932-20937.
15. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al.: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. *Science* 2007, **316**:1039-1043.
16. Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, et al.: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. *Cancer Res* 2008, **68**:9479-9487.
17. Huang S, Bjornsti MA, Houghton PJ: Rapamycins: mechanism of action and cellular resistance. *Cancer Biol Ther* 2003, **2**:222-232.
18. Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, Khuri FR: Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. *Cancer Res* 2005, **65**:7052-7058.
19. Lee H, Kim SJ, Jung KH, Son MK, Yan HH, Hong S, Hong SS: A novel imidazopyridine PI3K inhibitor with anticancer activity in non-small cell lung cancer cells. *Oncol Rep* 2013.
20. Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S: The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. *Int J Cancer* 2013, **133**:505-513.
21. Zito CR, Jilaveanu LB, Anagnostou V, Rimm D, Bepler G, Maira SM, Hackl W, Camp R, Kluger HM, Chao HH: Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells. *PLoS One* 2012, **7**:e31331.
22. Carriere A, Romeo Y, Acosta-Jaquez HA, Moreau J, Bonneil E, Thibault P, Fingar DC, Roux PP: ERK1/2 phosphorylate

- Raptor to promote Ras-dependent activation of mTOR complex 1 (mTORC1). *J Biol Chem* 2011, **286**:567-577.
23. Li D, Shimamura T, Ji H, Chen L, Haringsma HJ, McNamara K, Liang MC, Perera SA, Zaghlul S, Borgman CL, et al.: **Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.** *Cancer Cell* 2007, **12**:81-93.
 24. Shimamura T, Li D, Ji H, Haringsma HJ, Liniker E, Borgman CL, Lowell AM, Minami Y, McNamara K, Perera SA, et al.: **Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance.** *Cancer Res* 2008, **68**:5827-5838.
 25. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G: **Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.** *Mol Cancer Ther* 2006, **5**:2676-2684.
 26. Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, et al.: **Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations.** *Oncogene* 2013, **32**:4427-4435.
 27. Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al.: **mTOR Inhibitors Control the Growth of EGFR Mutant Lung Cancer Even after Acquiring Resistance by HGF.** *PLoS One* 2013, **8**:e62104.
 28. Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S: **Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.** *Clin Cancer Res* 2011, **17**:2260-2269.
 29. Jiang Y, Zhang Y, Luan J, Duan H, Zhang F, Yagasaki K, Zhang G: **Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action.** *Cytotechnology* 2010, **62**:573-583.
 30. Kang XH, Xu ZY, Gong YB, Wang LF, Wang ZQ, Xu L, Cao F, Liao MJ: **Bufalin Reverses HGF-Induced Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer Cells via Blockage of Met/PI3k/Akt Pathway and Induction of Apoptosis.** *Evid Based Complement Alternat Med* 2013, **2013**:243859.
 31. Zhu Z, Sun H, Ma G, Wang Z, Li E, Liu Y, Liu Y: **Bufalin Induces Lung Cancer Cell Apoptosis via the Inhibition of PI3K/Akt Pathway.** *Int J Mol Sci* 2012, **13**:2025-2035.
 32. Choi YJ, Rho JK, Jeon BS, Choi SJ, Park SC, Lee SS, Kim HR, Kim CH, Lee JC: **Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.** *Cancer Chemother Pharmacol* 2010, **66**:381-388.
 33. Kim SM, Yun MR, Hong YK, Solca F, Kim JH, Kim HJ, Cho BC: **Glycolysis Inhibition Sensitizes Non-Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation.** *Mol Cancer Ther* 2013.
 34. **Clinical trials on combinatory inhibition of PI3K/AKT/mTOR pathway with EGFR TKIs in non-small cell lung cancer.** 2013. [Online]. Available: <http://www.trialsunited.com>.
 35. **Clinical trials on combinatory inhibition of PI3K/AKT/mTOR pathway with EGFR TKIs in non-small cell lung cancer.** 2013. [Online] Available: <http://clinicaltrials.gov>.
 36. **Boehringer Ingelheim: U.S. FDA approves Gilotrif™ (afatinib)* as first-line treatment for lung cancer patients with EGFR mutations.** http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2013/15_july_2013_oncology.html 2013.
 37. Jay A, Friedman RD, Sheila Miknyoczki, Mangeng Cheng, Robert Hudkins, Bruce Dorsey, Mark Ator, Thelma Angeles, Bruce Ruggeri, Elizabeth Bruckheimer. : **Antitumor activity of the dual AXL/c-Met inhibitor CEP-40783 in Champions primary TumorGraft™ models of human non-small cell lung cancer (NSCLC).** AACR-NCLC-EORTC International Conference on Molecular Targets and Cancer Therapeutics #C272. October 19-23, 2013. Boston, MA.
 38. Schoeberl B, Faber AC, Li D, Liang MC, Crosby K, Onsum M, Burenkova O, Pace E, Walton Z, Nie L, et al.: **An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.** *Cancer Res* 2010, **70**:2485-2494.

Note: Vedic Research International, Vedic Research Inc. does not responsible for any data in the present article including, but not limited to, writeup, figures, tables. If you have any questions, directly contact authors.

Visit us @ www.vedicjournals.com : DOI: <http://dx.doi.org/10.14259/or.v1i1.81>

Copyright © 2013 VRI Press, Vedic Research, Inc. USA. All rights reserved.

Authors Column



Dr. Song is a postdoctoral fellow at Yale University School of Medicine. She got her Ph.D. at Iowa State University, where she received training in genetics, molecular biology, and biochemistry. During her postdoc, her research is focused on cancer biology, signal transduction, and mouse modeling of human lung cancer. Currently, Dr. Song is studying the role of ERBB2 and ERBB3 in mutant EGFR-mediated lung tumorigenesis and drug resistance. Dr. Song is a grant recipient of the Uniting Against Lung Cancer 2012 Legacy Program. She received the 2013 Leslie H. Warner Postdoctoral Fellowship for Cancer Research from Yale Cancer center.